# US 2020/0390810 A1 · Subject-Specific Tumor Inhibiting Cells and the Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390810 A1
- Document ID: US20200390810A1
- Status: Published application
- Kind: A1
- Application number: 16/762,934
- Filed: 2018-12-14
- Published: 2020-12-17
- Earliest claimed: 2017-12-14
- Assignees: EZY Biotech LLC; Adaerata, Limited Partnership
- Applicants: Ezy Biotech LLC; Adaerata, Limited Partnership
- Inventors: HUA GU; Gang G Xu; Adeline Gadzinski; Haijun Tong
- Web page: https://patentgrep.com/patent/US20200390810A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure is directed to a pharmaceutical composition comprises tumor inhibiting cells (TICs) and a method for producing the TICs. The tumor inhibiting cells can be derived from immune cells including T cells, NK cells, or a combination thereof, modified to have inactivated Cbl-b gene alleles and free from Cbl-b bio-function (Cbl-b−/− TICs). The Cbl-b−/− TICs are free from deoxyribonucleic acids exogenous to the immune cells. The immune cells can be isolated using a portable cell isolation and modification device. This disclosure is further directed to a method for treating tumorous conditions in subjects. The pharmaceutical composition can provide a subject-specific tumor treatment.

## Claims

### Claim 1

A pharmaceutical composition comprising a population of Cbl-b−/− tumor inhibiting cells (Cbl-b−/− TICs) modified from immune cells, wherein the Cbl-b−/− TICs have inactivated Cbl-b genomic alleles and are free from Cbl-b bio-function, and wherein the Cbl-b−/− TICS are free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids exogenous to the immune cells.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Cbl-b−/− TICs comprise Cbl-b−/− T cells, Cbl-b−/− CD8+ T cells, Cbl-b−/− NK cells, or a combination thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the Cbl-b−/− TICs are histological compatible to a subject.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the immune cells are from peripheral blood of the subject, lymph organs of the subject, lymph fluids of the subject, an organ of the subject, a tissue of the subject, tumor infiltrating lymphocytes (TILs) from a tumor of the subject, a xenograft tumor derived from the tumor of the subject, or a combination thereof.

### Claim 6

(canceled)

### Claim 7

A method for producing Cbl-b−/− tumor inhibiting cells (TICs), the method comprising the steps of:
a) inactivating genomic Cbl-b genes of immune cells to produce the Cbl-b−/− TICs, wherein the Cbl-b−/− TICs are free from Cbl-b bio-function and free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids exogenous to the immune cells;
b) optionally, propagating the Cbl-b−/− TICs in in vitro cell culture; and
c) optionally, harvesting the Cbl-b−/− TICs from the in vitro cell culture.

### Claim 8 (depends on 7)

The method of claim 7, wherein the genomic Cbl-b genes are inactivated by introducing into the immune cells a genomic modification component comprising a Cas9 protein and a sgRNACbl-b targeting the genomic Cbl-b genes of the immune cells, and wherein the genomic modification component is free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids.

### Claim 9 (depends on 8)

The method of claim 8, wherein said sgRNACbl-b comprises a nucleic acid sequence GAGGUCCACCAGAUUAGCUCUGG (SEQ ID. 1), a nucleic acid sequence having homology in a range of from 80% to 100% to the sequence of said SEQ ID. 1, or a combination thereof.

### Claim 10 (depends on 7)

The method of claim 7, wherein the immune cells comprise unmodified T cells, unmodified NK cells, or a combination thereof.

### Claim 11 (depends on 7)

The method of claim 7, wherein immune cells comprise purified unmodified T cells.

### Claim 12 (depends on 7)

The method of claim 7, wherein the immune cells are tumor infiltrating lymphocytes (TILs) from a tumor of a subject, a xenograft tumor derived from the tumor of the subject, or a combination thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein said immune cells are tumor infiltrating T cells isolated from said tumor of said subject, and optionally expanded, wherein said subject is a human subject.

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 7)

The method of claim 7, wherein the Cbl-b−/− TICs comprise Cbl-b−/− T cells, Cbl-b−/− CD8+ T cells, Cbl-b−/− NK cells, or a combination thereof.

### Claim 17 (depends on 7)

The method of claim 7, wherein the Cbl-b−/− TICs comprise in a range of from 10% to 100% of Cbl-b−/− T cells, percentage based on total population of the Cbl-b−/− TICs.

### Claim 18

(canceled)

### Claim 19

A method for treating a tumorous condition of a subject in need thereof, the method comprising the steps of:
a) inactivating genomic Cbl-b genes of immune cells of the subject to produce Cbl-b−/− tumor inhibiting cells (TICs), wherein the Cbl-b−/− TICs have inactivated Cbl-b gene alleles and are free from Cbl-b bio-function, and wherein the Cbl-b−/− TICs are free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids exogenous to the immune cells;
b) optionally, propagating the Cbl-b−/− TICs in in vitro cell culture; and
c) administering the Cbl-b−/− TICs to the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the genomic Cbl-b genes are inactivated by introducing into the immune cells a genomic modification component comprising a Cas9 protein and a sgRNACbl-b targeting the genomic Cbl-b genes of the immune cells, and wherein the genomic modification component is free from deoxyribonucleic acids exogenous to the immune cells and free from viral nucleic acids.

### Claim 21 (depends on 20)

The method of claim 20, wherein the Cas9 protein is a modified recombinant Cas9 protein comprising a C-Terminal nuclear localization signal region from an unmodified Cas9 protein.

### Claim 22 (depends on 19)

The method of claim 19, wherein the Cbl-b−/− TICs comprise Cbl-b−/− T cells, Cbl-b−/− CD8+ T cells, Cbl-b−/− NK cells, or a combination thereof, wherein the immune cells are from peripheral blood of the subject, lymph organs of the subject, lymph fluids of the subject, tumor infiltrating lymphocytes (TILs) from a tumor of the subject, a xenograft tumor derived from the tumor of the subject, or a combination thereof, or a combination thereof and wherein said subject is a human subject.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 19)

The method of claim 19, wherein said subject has two or more different tumors.

### Claim 26 (depends on 19)

The method of claim 19, wherein the number of Cbl-b−/− TICs administered to the subject is in a range of from about 1×105 to about 5×107 cells/kg and wherein said Cbl-b−/− TICs are administrated to the subject by injection, infusion or a combination thereof.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 19)

The method of claim 19, further comprising administering said subject a cancer drug, a checkpoint inhibitor, or a combination thereof.

### Claim at position 31

31-62. (canceled)
